Def Leppard Guitarist Receiving Treatment for Hodgkin's
Rock guitarist Vivian Campbell, currently playing with Def Leppard, announced Monday that he has been receiving chemotherapy for Hodgkin's lymphoma.
Campbell, who had previously played in Dio and Whitesnake, among other bands, says he had a "cough that wouldn't quit" which alerted him to see a doctor.
The National Cancer Institute estimates that fewer than 10,000 people in the U.S. will be diagnosed with Hodgkin's annually.
At 50, Campbell is a bit on the older side for such a diagnosis, as about 60 percent of Hodgkin's diagnoses are made in people under the age of 45.
The guitarist made the announcement on Def Leppard's Facebook page, making light of the situation:
The reason I’m sharing this with you is because, despite cancer and chemo, me and my new aerodynamic hairstyle (read: no hair) are going on tour this summer with the band and I don’t want anyone to be so shocked by my new look that they ask for a refund. Simple economics, really.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
